Mini Review
Accepted on 25 Jun 2025
Pharmacogenetics or Predictive Genetics? APOE Testing Blurs the Lines
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1627239
Type at least 3 characters
2,466 articles
Correction
Accepted on 25 Jun 2025
Novel multitarget analgesic candidate SZV-1287 demonstrates potential disease-modifying effects in the monoiodoacetate-induced osteoarthritis mouse model
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1646562
Review
Published on 25 Jun 2025
Gut-brain axis in post-traumatic stress disorder: microbial - mediated mechanisms and new therapeutic approaches - A narrative review
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1621678
- 156 views
Editorial
Published on 25 Jun 2025
Editorial: Innovative therapies against neurodegenerative disorders: from new active molecules to novel drug delivery systems
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1640758
- 244 views
Review
Published on 25 Jun 2025
Ketogenic therapy for schizophrenia: evidence, mechanisms, and clinical perspectives
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1603722
- 458 views
Mini Review
Published on 24 Jun 2025
Research on the effects of GLP-1 receptor agonists in treating cognitive dysfunction and gait disorders in elderly patients with diabetes
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1607443
- 283 views
Original Research
Accepted on 23 Jun 2025
Ramipril and ketogenic diet response in cognitive dysfunction of insulin-resistant rats
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1620139
Review
Published on 23 Jun 2025
Unveiling the therapeutic potential of natural products in Alzheimer’s disease: insights from in vitro, in vivo, and clinical studies
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1601712
- 780 views
Original Research
Accepted on 20 Jun 2025
Acute Pharmacological Effects of α-PVP in Humans: A Naturalistic Observational study
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1626692
- 123 views
Review
Accepted on 20 Jun 2025
Orexin-A and Motion Sickness: A Systematic Review of Animal Model Studies
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1624080
Review
Accepted on 20 Jun 2025
Preclinical and Experimental Evidence of Salvianolic Acid B in the Treatment of Neurological Diseases
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1606146
Hypothesis and Theory
Accepted on 20 Jun 2025
The Antipsychotics Functional Index (AFI) in Schizophrenia
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1591763
Original Research
Published on 20 Jun 2025
Age-specific effects of synthetic cannabinoids on cognitive function and hippocampal gene expression in mice: insights from behavioral and molecular correlates
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1618929
- 332 views
Original Research
Published on 20 Jun 2025
Network pharmacology-based prediction and “gut microbiota-inflammation-brain axis” validation of the active ingredients and potential mechanisms of Plantagins Herba for treating diabetes-related cognitive dysfunction
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1601689
- 381 views
Review
Published on 19 Jun 2025
Plant-derived polyphenolic compounds for managing schizophrenia: mechanisms and therapeutic potential
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1605027
- 330 views
Original Research
Accepted on 18 Jun 2025
Preclinical Pharmacology of Alogabat: A Novel GABAA-α5 Positive Allosteric Modulator Targeting Neurodevelopmental Disorders with Impaired GABAA Signaling
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1626078
- 129 views